MedTrace Logo

Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer

NCT00645866 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2011-05-16

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy, such as epirubicin, docetaxel, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This phase II trial is studying the side effects of giving epirubicin together with docetaxel and capecitabine and to see how well it works in treating women with stage IIIA or stage IIIB breast cancer.

Conditions

Interventions

DRUG

capecitabine

DRUG

docetaxel

DRUG

epirubicin hydrochloride

OTHER

laboratory biomarker analysis

OTHER

pharmacogenomic studies

PROCEDURE

biopsy

PROCEDURE

neoadjuvant therapy

PROCEDURE

therapeutic surgical procedure

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Julian R. Molina, MD, PhD · Mayo Clinic

  • James N. Ingle, MD · Mayo Clinic

  • Wilma Lingle, PhD · Mayo Clinic

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-04-30
Primary Completion
2006-03-31
Completion
2006-03-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00645866 on ClinicalTrials.gov